Veraxa Biotech Holding AG SEC filings VRXAW
Veraxa Biotech Holding AG has 56 filings in SEC EDGAR's recent list, going back to Jul 31, 2025. Its latest annual report, Form 20-F, was filed on Jun 16, 2026 for the period ended Dec 31, 2025. The most recent current report (Form 6-K) was filed on Oct 15, 2026. The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Oct 15, 2026 | Oct 15, 2026 |
| 424B3 | Prospectus | Sep 4, 2026 | — |
| 424B3 | Prospectus | Sep 4, 2026 | — |
| 6-K | Current report (foreign issuer) | Sep 4, 2026 | Sep 4, 2026 |
| 6-K | Current report (foreign issuer) | Aug 24, 2026 | Aug 24, 2026 |
| 424B5 | Prospectus supplement | Aug 10, 2026 | — |
| 424B5 | Prospectus supplement | Aug 10, 2026 | — |
| EFFECT | Filing | Aug 6, 2026 | — |
| EFFECT | Filing | Aug 6, 2026 | — |
| F-1/A | Filing | Aug 5, 2026 | — |
| F-1/A | Filing | Aug 5, 2026 | — |
| F-1 | Registration statement (foreign issuer) | Jul 31, 2026 | — |
| F-1 | Registration statement (foreign issuer) | Jul 31, 2026 | — |
| 6-K | Current report (foreign issuer) | Jul 31, 2026 | Jul 31, 2026 |
| 6-K | Current report (foreign issuer) | Jul 27, 2026 | Jul 27, 2026 |
| 6-K | Current report (foreign issuer) | Jul 27, 2026 | Jul 27, 2026 |
| 6-K | Current report (foreign issuer) | Jun 18, 2026 | Jun 18, 2026 |
| 20-F | Annual report (foreign issuer) | Jun 16, 2026 | Dec 31, 2025 |
| 6-K | Current report (foreign issuer) | Jun 11, 2026 | Jun 10, 2026 |
| CERT | Filing | Jun 10, 2026 | — |
| 8-A12B/A | Filing | Jun 10, 2026 | — |
| 8-A12B | Filing | Jun 9, 2026 | — |
| 424B3 | Prospectus | Feb 19, 2026 | — |
| EFFECT | Filing | Feb 17, 2026 | — |
| CORRESP | Letter to the SEC | Feb 13, 2026 | — |
| F-4/A | Filing | Feb 13, 2026 | — |
| CORRESP | Letter to the SEC | Feb 12, 2026 | — |
| UPLOAD | Letter from the SEC | Feb 11, 2026 | — |
| F-4/A | Filing | Feb 3, 2026 | — |
| CORRESP | Letter to the SEC | Nov 28, 2025 | — |
| F-4/A | Filing | Nov 28, 2025 | — |
| UPLOAD | Letter from the SEC | Nov 20, 2025 | — |
| 425 | Filing | Sep 30, 2025 | — |
| F-4/A | Filing | Sep 29, 2025 | — |
| CORRESP | Letter to the SEC | Sep 29, 2025 | — |
| UPLOAD | Letter from the SEC | Aug 27, 2025 | — |
| F-4/A | Filing | Jul 31, 2025 | — |
| F-4 | Filing | Jul 31, 2025 | — |
Showing 38 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- VRXA (Nasdaq), VRXAW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Switzerland
- Headquarters
- Zurich
- SEC filer status
- , Emerging growth company
- SEC CIK
- 2079109
- Former names
- Veraxa Biotech Holding AG (until Aug 13, 2026)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.